Handelsbanken Fonder AB Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Handelsbanken Fonder AB grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,502 shares of the biopharmaceutical company’s stock after buying an additional 3,998 shares during the quarter. Handelsbanken Fonder AB’s holdings in Regeneron Pharmaceuticals were worth $26,514,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of REGN. Bronte Capital Management Pty Ltd. grew its position in Regeneron Pharmaceuticals by 21.4% during the 2nd quarter. Bronte Capital Management Pty Ltd. now owns 187,870 shares of the biopharmaceutical company’s stock worth $98,632,000 after acquiring an additional 33,177 shares during the last quarter. Howe & Rusling Inc. increased its stake in Regeneron Pharmaceuticals by 10.7% in the 2nd quarter. Howe & Rusling Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $326,000 after purchasing an additional 60 shares during the period. Empirical Finance LLC lifted its position in Regeneron Pharmaceuticals by 18.3% in the second quarter. Empirical Finance LLC now owns 1,927 shares of the biopharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 298 shares during the last quarter. Seizert Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.0% during the second quarter. Seizert Capital Partners LLC now owns 85,980 shares of the biopharmaceutical company’s stock valued at $45,140,000 after purchasing an additional 3,308 shares during the period. Finally, ARS Investment Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 222.0% during the second quarter. ARS Investment Partners LLC now owns 20,855 shares of the biopharmaceutical company’s stock valued at $10,949,000 after purchasing an additional 14,378 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Bank of America raised their target price on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday, October 29th. Finally, Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $776.81.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $755.90 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $800.99. The stock has a market capitalization of $79.44 billion, a P/E ratio of 18.10, a P/E/G ratio of 2.03 and a beta of 0.31. The company’s 50-day moving average is $615.29 and its 200 day moving average is $575.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the firm posted $12.46 EPS. The business’s revenue was up .9% on a year-over-year basis. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.